

ASX ANNOUNCEMENT

27 May 2022

Cleansing notice under section 708AA(2)(f) of the *Corporations Act 2001* (Cth)

Reference is made to the Appendix 2A released to ASX on 25 May 2022 relating to the issue of 10,000 New Shares by Kazia Therapeutics Limited ACN 063 259 754 (**KZA**).

Information required under section 708AA(7) of the *Corporations Act*

For the purposes of section 708AA(7) of the *Corporations Act*, KZA advises as follows:

1. The New Shares were issued without disclosure under Part 6D.2 of the *Corporations Act* as notionally modified by the ASIC Instrument.
2. This notice is given under section 708AA(2)(f) of the *Corporations Act* as notionally modified by the ASIC Instrument.
3. As at the date of this notice, KZA has complied with:
 - (a) the provisions of Chapter 2M of the *Corporations Act* as they apply to KZA; and
 - (b) section 674 of the *Corporations Act*.
4. As at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the *Corporations Act*, as notionally modified by the ASIC Instrument.
5. Concerning the potential effect that the issue of the New Shares will have on the control of KZA, and the consequences of that effect, the issue of New Shares is not expected to have any material effect or consequence on the control of KZA.

Authorised for release by the Board of Directors.

Signed for and on behalf of KZA.



Kate Hill
Company Secretary